

REMARKS

Claims 4, 6-10, 14 and 15 are pending the application; all pending claims stand rejected. By this Amendment, Claims 6 and 8 have been amended. These amendments add no new matter to the application.

Claims 4, 6-10, 14 and 15 stand rejected under 35 USC 102b as allegedly anticipated by Snow 1994. The Examiner alleges that Snow 1994 teaches amyloid plaque infuse components for the formation of maltese cross plaques; but all of these plaques, which are not even maltese cross plaques, were generated with HSPG which is not the same as heparan sulfate as now more particularly claimed. In 1994, heparan sulfate was not known in use separate from HSPG, and none of the date in Snow 1994 is to the contrary. It is a particular contribution to the art that HS is now disclosed, under specified conditions, to lead to the desired maltese-cross pattern, which was not previously achieved. Therefore the Snow 1994 teaches away from the current claims and the pending claims do not read on Snow 1994 and are therefore in condition for allowance. Reconsideration is requested.

Claims 4, 6-10, 14 and 15 stand rejected under 35 USC 102b as allegedly anticipated by Castillo 1997. Castillo 1997 was reporting on binding studies only, not on plaque formations, and he says at page 2461, second paragraph, that EHS perlecan (which was the only substance used then in the study) could not be made to form plaques at all. It must again be distinguished, as to Castillo 1997, that not everything that binds forms plaques, and not every plaque is the preferred Maltese cross plaque, with “Maltese-cross pattern when stained with Congo red and viewed under polarized light, and an amyloid star appearance when viewed by transmission electron microscopy” which is the limitation as claimed. Therefore the Castillo 1997 teaches away from

the current claims and the pending claims do not read on Castillo 1997 and are therefore in condition for allowance. Reconsideration is requested.

Applicant believes that it has responded fully to all of the concerns expressed by the Examiner in the Office Action, and respectfully requests that early favorable action be taken on all claims pending in the application. Applicant respectfully requests reexamination of all rejected claims and early favorable action on them as well. If the Examiner has any further concerns, Applicant requests a call to Patrick Dwyer at (206) 343-7074.

Respectfully submitted,



PATRICK MICHAEL DWYER
Reg. No. 32,411

P08-RCE.RSP

PROTEOTECH, INC.
1818 WESTLAKE AVENUE N, SUITE 114
SEATTLE, WA 98109